VitaSpring Biomedical Cash Flow Statement

Financials in millions USD. Fiscal year is February - January.

Millions USD. Fiscal year is Feb - Jan.

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Apr '26 Apr 30, 2026	Jan '26 Jan 31, 2026	Jan '25 Jan 31, 2025	Jan '24 Jan 31, 2024	Jan '23 Jan 31, 2023	Jan '22 Jan 31, 2022
Net Income	-0.41	-0.42	-0.77	-1.12	-4.16	0.91
Depreciation & Amortization	0.01	0.01	0.01	0.02	0.02	0.01
Asset Writedown & Restructuring Costs	-	-	-	0.01	-	-
Stock-Based Compensation	-	-	0.11	0.16	0.19	0.17
Provision & Write-off of Bad Debts	-	-	-	-	0.03	-
Other Operating Activities	-	-	0.09	0.17	0.2	0.01
Change in Accounts Receivable	-	-	-	0.38	2.54	-2.95
Change in Inventory	-	-	-	-	-	0.14
Change in Accounts Payable	0.18	0.16	0.16	0.28	1.18	1.25
Change in Income Taxes	0.02	0.03	0.1	-	0.01	0.21
Change in Other Net Operating Assets	0.21	0.21	0.3	0.06	-0.08	-0.02
Operating Cash Flow	0	-0	-0.01	-0.03	-0.08	-0.27
Capital Expenditures	-	-	-	-	-	-0.07
Investing Cash Flow	-	-	-	-	-	-0.07
Short-Term Debt Issued	-	0	0.01	0.01	-	-
Total Debt Issued	0	0	0.01	0.01	-	-
Net Debt Issued (Repaid)	0	0	0.01	0.01	-	-
Issuance of Common Stock	-	-	-	-	-	0.05
Financing Cash Flow	0	0	0.01	0.01	-	0.05
Miscellaneous Cash Flow Adjustments	-	-	-	-	-	0.35
Net Cash Flow	0.01	0	0	-0.03	-0.08	0.06
Free Cash Flow	0	-0	-0.01	-0.03	-0.08	-0.34
Free Cash Flow Margin	-	-	-	-	-	-6.10%
Free Cash Flow Per Share	-	-	-	-	-	-0.00
Cash Income Tax Paid	-	-	-	-	0	0
Levered Free Cash Flow	0.17	0.18	0.33	0.39	1.48	-0.19
Unlevered Free Cash Flow	0.17	0.18	0.33	0.39	1.48	-0.19
Change in Working Capital	0.4	0.4	0.55	0.73	3.65	-1.36